Knockdown of TRIM47 Attenuates Pressure Overload‐Induced Heart Failure by Inhibiting NLRP3 Inflammasome Activation
Cardiovascular Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/cdr/4678859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 21.11.2026. Verfasst von Jie Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, The Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliated to Yangzhou University), Huai'an, Jiangsu, …. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Heart Failure, Inflammasomes, Ventricular Function, Left. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
The ubiquitinated protein TRIM47 participates in the inflammatory regulation of various organ injuries, but its role in pressure overload‐induced heart failure remains unclear.
Objective
The aim of this study is to investigate the protective effect of TRIM47 knockdown against pressure overload‐induced myocardial injury.
Methods
A TAC mouse model of heart failure was established, and myocardial TRIM47 knockdown was achieved through targeted cardiac injection of AAV‐sh‐TRIM47. Heart weight/body weight ratio (HW/BW) and heart weight/tibia length ratio (HW/TL) were measured, and ANP/BNP mRNA levels were used to assess myocardial injury. HE and WGA staining were used to observe cardiomyocyte hypertrophy; Masson and Sirius red staining were used to detect myocardial fibrosis; TUNEL staining and apoptosis‐related protein analysis were used to detect cardiomyocyte apoptosis; and Western blotting was used to detect the expression levels of key molecules in the NLRP3 inflammasome.
Results
TRIM47 was highly expressed in the left ventricle of mice with heart failure. In the TAC group, mice showed increased HW/BW and HW/TL ratios, as well as elevated ANP and BNP mRNA levels. Cardiomyocyte hypertrophy, disordered myofiber arrangement, increased collagen deposition and expression of fibrosis‐related proteins, and myocardial apoptosis were observed. Increased expression of inflammasome activation‐related proteins, including NLRP3, cleaved caspase‐1, mature IL‐1 β , and IL‐18 was also observed. Knockdown of TRIM47 reversed these pathological changes.
Conclusion
TRIM47 is abnormally upregulated in the myocardium in pressure overload‐induced heart failure. TRIM47 knockdown alleviates TAC‐induced heart failure by inhibiting myocardial hypertrophy, fibrosis, apoptosis, and NLRP3 inflammasome activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, The Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliated to Yangzhou University), Huai'an, Jiangsu, China.
- Yangzhou University Huai'an Medical Collaborative Innovation Center, Huai'an, Jiangsu, China.
- Department of Cardiology, The Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliated to Yangzhou University), Huai'an, Jiangsu, China.
- Department of Critical Care Medicine, The Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliated to Yangzhou University), Huai'an, Jiangsu, China.
ORCID-Profile: Jie Li
Zitieren
APA
Li, J., Bao, L., Liu, Z., Zhang, J., Zhang, Y., Sun, X., & Sun, B. (2026). Knockdown of TRIM47 Attenuates Pressure Overload‐Induced Heart Failure by Inhibiting NLRP3 Inflammasome Activation. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/4678859
Vancouver
Li J, Bao L, Liu Z, Zhang J, Zhang Y, Sun X, et al. Knockdown of TRIM47 Attenuates Pressure Overload‐Induced Heart Failure by Inhibiting NLRP3 Inflammasome Activation. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/4678859
BibTeX
@article{Li2026,
author = {Li, Jie and Bao, Lei and Liu, Zhou and Zhang, Jing and Zhang, Yan and Sun, Xuejiao and Sun, Beibei},
title = {Knockdown of TRIM47 Attenuates Pressure Overload‐Induced Heart Failure by Inhibiting NLRP3 Inflammasome Activation},
journal = {Cardiovascular Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cdr/4678859}
}
EUVIMED